Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
52,953 Cancer
clinical trials

Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fruitland, ID
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Garden City, KS
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Grafton, WI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Harbor City, CA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hutchinson, MN
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Independence, KS
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, NC
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jefferson, IA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kalispell, MT
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kenner, LA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kennewick, WA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kirkland, WA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Crosse, WI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lawrence, KS
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lenexa, KS
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Livonia, MI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lynnwood, WA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Martinsburg, WV
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mentor, OH
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Monroeville, PA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mount Holly, NJ
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Natrona Heights, PA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
North Platte, NE
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oshkosh, WI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ottawa, IL
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Paoli, PA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Paramus, NJ
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Perrysburg, OH
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenixville, PA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pittsfield, MA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Post Falls, ID
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Provo, UT
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ridgewood, NJ
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rockford, IL
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saginaw, MI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salina, KS
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Scarborough, ME
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Scottsbluff, NE
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seneca, SC
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Southfield, MI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Springfield, MA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Research Site
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Traverse City, MI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Troy, OH
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Two Rivers, WI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Vallejo, CA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Warren, MI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Research Site
mi
from
West Branch, MI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Westwood, KS
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wilson, NC
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Winfield, KS
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Woodbury, MN
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
York, PA
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Clinical Research Facility
mi
from
Zanesville, OH
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Status: Enrolling, Phase I, II
Updated: 9/29/2017
Stanford University; Division of Pediatric Stem Cell Transplant & Regenerative Medicine
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Differentiated Thyroid Cancer Clinical Trial
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 3/15/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Differentiated Thyroid Cancer Clinical Trial
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 3/15/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Differentiated Thyroid Cancer Clinical Trial
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 3/15/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Differentiated Thyroid Cancer Clinical Trial
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 3/15/2016
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Breast Cancer Clinical Trial
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Status: Enrolling, Phase I, II
Updated: 12/31/1969
UPMC- Hillman Cancer Center-Monroeville
mi
from
Monroeville, PA
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling, Phase III
Updated: 9/23/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling, Phase III
Updated: 9/23/2015
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling, Phase III
Updated: 9/23/2015
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Non Small Cell Lung Cancer Clinical Trial
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Melbourne,
Click here to add this to my saved trials
Oncology Clinical Trial
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
Status: Enrolling, Phase I
Updated: 12/31/1969
City of Hope West Covina
mi
from
West Covina, CA
Click here to add this to my saved trials
Oncology Clinical Trial
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Status: Enrolling, Phase II, III
Updated: 11/22/2016
Medizinische Universitat Innsbruck
mi
from
Innsbruck,
Click here to add this to my saved trials
Colorectal Cancer Clinical Trial
Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer
Status: Enrolling
Updated: 5/30/2017
Baptist Medical Group Oncology
mi
from
Pensacola, FL
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Pali Momi Medical Center
mi
from
'Aiea, HI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
The Cancer Center of Hawaii-Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Joseph Mercy Brighton
mi
from
Brighton, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Aurora Cancer Care-Southern Lakes VLCC
mi
from
Burlington, WI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
AtlantiCare Health Park-Cape May Court House
mi
from
Cape May Court House, NJ
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Joseph Mercy Chelsea
mi
from
Chelsea, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Newland Medical Associates-Clarkston
mi
from
Clarkston, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
AdventHealth Infusion Center Haywood
mi
from
Clyde, NC
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Integrity Oncology PLLC-Collierville
mi
from
Collierville, TN
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
UM Sylvester Comprehensive Cancer Center at Coral Gables
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Northshore Oncology Associates-Covington
mi
from
Covington, LA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
North Shore Oncology Hematology Associates-Crystal Lake
mi
from
Crystal Lake, IL
Click here to add this to my saved trials